NasdaqGM:HROWPharmaceuticals
Harrow (HROW) Is Up 8.1% After Launching PharmaPack Cash-Pay Ophthalmic Kits For Cataract Surgery
In February 2026, Harrow, Inc. launched PharmaPack, a direct-to-prescriber cash-pay kit program that offers affordable, fully priced-upfront FDA-approved ophthalmic products as alternatives to off-label compounded formulations for cataract surgery patients, while bypassing insurance hurdles.
This move could be important for eye surgeons and patients because it aims to simplify access, reduce regulatory and medical-legal risk, and potentially shift prescribing away from compounded products...